Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 114

    1.

    Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.

    Seo YR, Kim SH, Kim HJ, Kim CK, Park SK, Koh ES, Hong DS.

    J Hematol Oncol. 2010 Jan 20;3:4.

    PMID:
    20089186
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.

    Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W.

    J Clin Oncol. 2000 May;18(9):1921-7.

    PMID:
    10784633
    [PubMed - indexed for MEDLINE]
    3.

    Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.

    Neri B, Vannini L, Giordano C, Grifoni R, Pantaleo P, Baldazzi V, Crisci A, Lapini A, Raugei A, Carini M.

    Anticancer Drugs. 2007 Nov;18(10):1207-11.

    PMID:
    17893522
    [PubMed - indexed for MEDLINE]
    4.

    [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].

    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.

    Hinyokika Kiyo. 1988 Aug;34(8):1371-5. Japanese.

    PMID:
    3195405
    [PubMed - indexed for MEDLINE]
    5.

    Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.

    Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P.

    Ann Oncol. 1999 Nov;10(11):1385-8.

    PMID:
    10631471
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.

    Kattan J, Culine S, Theodore C, Droz JP.

    Cancer Invest. 1995;13(3):276-9.

    PMID:
    7743380
    [PubMed - indexed for MEDLINE]
    7.

    Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.

    Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G.

    Br J Cancer. 2005 Feb 28;92(4):645-50.

    PMID:
    15685232
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].

    Inoue T, Ohyama C, Horikawa Y, Togashi H, Matsuura S, Tsuchiya N, Satoh S, Sato K, Habuchi T, Saito S, Hoshi S, Arai Y, Kato T.

    Hinyokika Kiyo. 2004 Apr;50(4):273-7. Japanese.

    PMID:
    15188623
    [PubMed - indexed for MEDLINE]
    9.

    Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

    Ecke TH, Bartel P, Koch S, Ruttloff J, Theissig F.

    Oncol Rep. 2006 Dec;16(6):1381-8.

    PMID:
    17089065
    [PubMed - indexed for MEDLINE]
    10.

    M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

    Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, et al.

    J Urol. 1988 Mar;139(3):461-9.

    PMID:
    3343727
    [PubMed - indexed for MEDLINE]
    11.

    Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.

    Takahashi T, Higashi S, Nishiyama H, Segawa T, Nakamura E, Kinoshita H, Itoh N, Yamamoto S, Kamoto T, Habuchi T, Ogawa O.

    Jpn J Clin Oncol. 2006 Feb;36(2):104-8. Epub 2006 Jan 17.

    PMID:
    16418182
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.

    Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C, et al.

    Cancer Chemother Pharmacol. 1992;30 Suppl:S72-6.

    PMID:
    1394823
    [PubMed - indexed for MEDLINE]
    13.

    Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.

    Ohtani H, Arimoto Y, Nishio K, Kanamiya Y, Oba H, Adachi K, Shintani M, Nakamura R, Yui S.

    Gan To Kagaku Ryoho. 2008 Oct;35(10):1769-74.

    PMID:
    18931586
    [PubMed - indexed for MEDLINE]
    14.

    Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.

    Ogawa T, Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Kamidono S.

    Cancer Chemother Pharmacol. 1992;30 Suppl:S66-71.

    PMID:
    1394822
    [PubMed - indexed for MEDLINE]
    15.

    [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].

    Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M.

    Urologe A. 2003 Aug;42(8):1074-86. Epub 2003 Apr 2. German.

    PMID:
    14513232
    [PubMed - indexed for MEDLINE]
    16.

    Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

    Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group.

    Cancer. 2002 Aug 15;95(4):751-7.

    PMID:
    12209718
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al.

    Cancer. 1989 Dec 15;64(12):2448-58.

    PMID:
    2819654
    [PubMed - indexed for MEDLINE]
    18.

    Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.

    Hoshi S, Ohyama C, Ono K, Takeda A, Yamashita S, Yamato T, Itoh A, Satoh M, Saito S, Okada Y, Sohma F, Arai Y.

    Int J Clin Oncol. 2004 Apr;9(2):125-9.

    PMID:
    15108045
    [PubMed - indexed for MEDLINE]
    19.

    Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.

    Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED; Southwest Oncology Group.

    Clin Genitourin Cancer. 2008 Mar;6(1):36-9.

    PMID:
    18501081
    [PubMed - indexed for MEDLINE]
    20.

    A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.

    Winquist E, Wilson JJ, Dorreen M, Wong R, Jonker D, Iscoe N.

    Can J Urol. 2004 Dec;11(6):2445-9.

    PMID:
    15636670
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk